Pro-Assurance Corp is a specialized insurance and risk management company that primarily focuses on providing professional liability and other related insurance solutions to healthcare providers and professionals
With a strong emphasis on serving the medical community, the company offers a range of products designed to protect against various risks, including malpractice claims. Pro-Assurance also engages in reinsurance activities, extending its expertise in risk assessment and management to help organizations minimize their exposure to liability. Through its commitment to quality service, Pro-Assurance aims to support the healthcare sector while ensuring the financial stability of its policyholders.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ProAssurance Corporation (NYSE: PRA) to The Doctors Company. Under the terms of the proposed transaction, shareholders of ProAssurance will receive $25.00 in cash for each share of ProAssurance that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ProAssurance Corporation (NYSE: PRA) to The Doctors Company for $25.00 in cash per share is fair to ProAssurance shareholders.
The Ademi Firm is investigating ProAssurance (NYSE: PRA) for possible breaches of fiduciary duty and other violations of law in its transaction with The Doctors Company.
The Doctors Company, the nation’s largest physician-owned medical malpractice insurer, and ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical liability, products liability for medical technology and life sciences, and workers’ compensation insurance, today announced that they have entered into a definitive agreement under which ProAssurance will be acquired by The Doctors Company. Under the terms of the agreement, ProAssurance stockholders will receive $25.00 in cash per share, representing an approximately 60% premium to the closing price per share of ProAssurance common stock on March 18, 2025, the last trading day prior to today’s announcement, with a transaction value of approximately $1.3 billion. The combined company will have assets of approximately $12 billion.
ProAssurance adopts a defensive strategy amid rising jury verdicts and social inflation, with a 14% stock surge and a $20 price target from analyst Matthew Carletti.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability and a core small-cap value equity in the financials sector, today reported net income of $16.2 million, or $0.31 per diluted share, and operating income(1) of $18.3 million, or $0.36 per diluted share, for the three months ended December 31, 2024. For full-year 2024, ProAssurance reported net income of $52.7 million, or $1.03 per diluted share, and operating income(1) of $48.6 million, or $0.95 per diluted share.
ProAssurance Corporation (NYSE: PRA) will issue its news release and file its Form 10-K after the market closes on Monday, February 24, 2025. The release and 10-K will be available on the Company’s website at investor.proassurance.com.
HOUSTON, Jan. 24, 2025 (GLOBE NEWSWIRE) -- American National Group Inc. (the “Company”) (NYSE: ANG PRA) today announced that the Company will redeem (the “Redemption”) all the 16,000 outstanding shares of its 5.95% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series A (the “Series A Preferred Stock”) and the corresponding 16,000,000 depositary shares, each representing a 1/1,000th interest in one share of Series A Preferred Stock (the “Depositary Shares”), on February 24, 2025 (the “Redemption Date”).
